Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension

S. Harutyunova (Heidelberg, Germany), N. Benkamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), A. Marra (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)

Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Session: Pulmonary arterial hypertension: recent advances from the bedside
Session type: Poster Discussion
Number: 5463
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Harutyunova (Heidelberg, Germany), N. Benkamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), A. Marra (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), E. Grünig (Heidelberg, Germany). Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension. 5463

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019



Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006

Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004

One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 324s
Year: 2001

Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 205s
Year: 2005

Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003

Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 660s
Year: 2006

Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol
Source: Eur Respir J 2001; 18: Suppl. 33, 323s
Year: 2001

Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001



Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 1334-1335
Year: 2001


Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 18: 247
Year: 2001


Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009


Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006



Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension
Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management
Year: 2017


Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013

The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 295s
Year: 2005

Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004


Successful artocoronary bypass grafting in a patient with severe idiopathic pulmonary arterial hypertension: use of intravenous treprostinil
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006

Efficacy of oral add-on therapy in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009